Skip to main content
Przejdź do strony domowej Komisji Europejskiej (odnośnik otworzy się w nowym oknie)
polski pl
CORDIS - Wyniki badań wspieranych przez UE
CORDIS

HARNESSING HETEROTYPIC T CELL CLUSTERS TO BOOST TIL CANCER THERAPY

Cel

Despite major advances in cancer immunotherapy, most patients still lack durable benefit. Tumor-infiltrating T lymphocyte (TIL) therapy can induce deep cancer remissions, but potency varies and complete clinical responses are limited to 20%. Crucially, although truly tumor-reactive T cells are rare in cancers (<5%), current manufacturing protocols expand TILs in bulk, without inclusion of a selection or enrichment step. Together, these observations create both a dire clinical need and unique opportunity to augment the impact of this type of immunotherapy, namely by selecting the actively tumor-killing T cells.
In our current ERC Advanced project ReverT, we discovered that tumor-killing T cells are strongly enriched in so-called heterotypic cell clusters: tight conjugates of T cells with tumor (melanoma) cells and/or antigen-presenting cells. We developed an isolation procedure to capture intact clusters straight from clinical cancer specimens from patients. These T cell clusters can be effectively expanded and exhibit a 9-fold increase in tumor-killing activity against patient tumors.
This ERC PoC project translates our findings into a “CLUSTER-TIL” manufacturing module, integrating upstream of the standard production pipeline to enable enhanced TIL therapy. We will develop and optimize a scalable procedure to purify cluster-derived T cells from tumor digests from patients, define quality metrics for tumor reactivity and benchmark to the standard bulk TIL workflow. CLUSTER-TIL will deliver a highly potent, consistent anti-cancer T cell therapy that will be tested in a planned investigator-initiated Phase 2a trial in melanoma. We observe similar clusters in other solid tumor types, enabling expansion to patient groups beyond melanoma. Furthermore, two patent applications protect the CLUSTER-TIL technology. This PoC will also generate follow-on IP to support a spin-off applying the technology for broader clinical implementation and improved patient outcomes.

Dziedzina nauki (EuroSciVoc)

Program(-y)

Temat(-y)

System finansowania

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

Wyświetl wszystkie projekty finansowane w ramach tego programu finansowania

Zaproszenie do składania wniosków

(odnośnik otworzy się w nowym oknie) ERC-2026-POC

Wyświetl wszystkie projekty finansowane w ramach tego zaproszenia

Instytucja przyjmująca

STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS
Wkład UE netto
€ 150 000,00
Koszt całkowity
Brak danych

Beneficjenci (1)